FDA Clears Malin's Hourglass Peripheral Embolization Plug

 

August 22, 2017—Malin Corporation plc, an Ireland-based company, announced that its Hourglass peripheral embolization plug was granted US Food and Drug Administration 510(k) clearance to commence marketing in the United States. The company stated that the Hourglass device is designed to provide precise, secure, over-the-wire delivery and immediate occlusion in a single integrated device. The device received European CE Mark approval in 2015.

In the company's announcement, Andrew Cragg, MD, commented, "The Hourglass device is designed to provide immediate occlusion in a wide range of vessel sizes with a single device. The device's unique design was created to take advantage of natural hemodynamic forces to provide immediate, focal, stable occlusions." Dr. Cragg, a Co-Developer of Hourglass, is an interventional radiologist in Minneapolis, Minnesota. The Hourglass device was a product of Emba Medical Limited, which Malin acquired in 2015.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.